Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly and Company to develop and commercialize treatments targeting cardiovascular and metabolic diseases. Olix will grant Eli ...
Hosted on MSN1mon
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHEli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback